Drugs / PEP-DC vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05195619 | Mar 2022 → Jun 2027 expected | non-small cell lung carcinoma | Centre Hospitalier Universitaire Vaudois | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04627246 | Sep 2020 → Sep 2028 expected | pancreatic adenocarcinoma | Centre Hospitalier Universitaire Vaudois | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP-DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04627246 ↗ |
| Modality | Vaccine | “PEP-DC vaccine: At least 5 subcutaneous vaccinations” NCT04627246 ↗ |
| Route | Subcutaneous | “PEP-DC vaccine: At least 5 subcutaneous vaccinations” NCT04627246 ↗ |